STOCK TITAN

TG Therapeutics Inc - TGTX STOCK NEWS

Welcome to our dedicated news page for TG Therapeutics (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on TG Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TG Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TG Therapeutics's position in the market.

Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announced financial results for 2023, highlighting key achievements such as initiating final IND/CTA enabling studies for PBGENE-HBV, completing licensing agreements with Imugene, TG Therapeutics, and Caribou Biosciences, and completing a $40 million public offering to extend cash runway. The company aims to submit IND and/or CTA for PBGENE-HBV in 2024 and PBGENE-PMM in 2025, advancing gene editing programs and differentiating ARCUS within the field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
earnings
-
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announced financial results for 2023, highlighting key achievements such as initiating final IND/CTA enabling studies for PBGENE-HBV, completing licensing agreements with Imugene, TG Therapeutics, and Caribou Biosciences, and completing a $40 million public offering to extend cash runway. The company aims to submit IND and/or CTA for PBGENE-HBV in 2024 and PBGENE-PMM in 2025, advancing gene editing programs and differentiating ARCUS within the field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
earnings
-
Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announced financial results for 2023, highlighting key achievements such as initiating final IND/CTA enabling studies for PBGENE-HBV, completing licensing agreements with Imugene, TG Therapeutics, and Caribou Biosciences, and completing a $40 million public offering to extend cash runway. The company aims to submit IND and/or CTA for PBGENE-HBV in 2024 and PBGENE-PMM in 2025, advancing gene editing programs and differentiating ARCUS within the field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
earnings
Rhea-AI Summary
TG Therapeutics, Inc. (TGTX) announces data presentations at the American Academy of Neurology 2024 meeting for BRIUMVI® in patients with multiple sclerosis. The presentations focus on the ULTIMATE I & II Phase 3 trials evaluating Ublituximab-xiiy, showcasing significant reductions in disease activity and improved disability outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.78%
Tags
none
-
Rhea-AI Summary
TG Therapeutics, Inc. (TGTX) presents data from Phase 3 trials on BRIUMVI® for multiple sclerosis at ACTRIMS forum. The trials show promising results with manageable safety profiles. CEO Michael S. Weiss expresses optimism for future trial updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
none
-
Rhea-AI Summary
TG Therapeutics, Inc. reported fourth-quarter and full-year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively. The company exceeded expectations with the BRIUMVI launch and set a revenue target of $220 - $260 million for 2024. They also announced positive developments in clinical trials, expanded clinical efforts, and partnerships. Financially, the company ended 2023 with a cash position of $217.5 million and reported a net loss of $14.4 million for the fourth quarter and net income of $12.7 million for the full year. TG Therapeutics is optimistic about its pipeline and aims to advance its recent addition, azer-cel, into clinical development for autoimmune disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.74%
Tags
earnings
Rhea-AI Summary
TG Therapeutics, Inc. announces the issuance of three additional patents by the USPTO for BRIUMVI (ublituximab-xiiy), extending patent protection for ublituximab and treatment methods until 2042. The patents leverage the unique glycoprofile of ublituximab, the first anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis in the US. Michael S. Weiss, Chairman and CEO, highlights the importance of life cycle management and the potential expansion of BRIUMVI's reach in multiple sclerosis and other autoimmune indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
none
-
Rhea-AI Summary
TG Therapeutics' ex-US partner, Neuraxpharm, launches BRIUMVI in Germany for the treatment of multiple sclerosis, triggering a milestone payment of $12.5 million to TG Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
-
Rhea-AI Summary
TG Therapeutics, Inc. (TGTX) will host a conference call on February 28, 2024, to discuss fourth-quarter and year-end 2023 results and provide a business outlook for 2024. The call will be led by Michael S. Weiss, Chairman, and CEO. Participants can join via phone or webcast. Financial results will be released in a press release before the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
conferences earnings
Rhea-AI Summary
TG Therapeutics, Inc. announces data presentations from Phase 3 trials for BRIUMVI® in patients with relapsing forms of multiple sclerosis at ACTRIMS annual forum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
none
TG Therapeutics Inc

Nasdaq:TGTX

TGTX Rankings

TGTX Stock Data

2.35B
134.88M
9.08%
59.33%
22.14%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About TGTX

tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".